Exemestane Substantially Reduces Breast Cancer Risk


June 30, 2011

NCI Cancer Bulletin

Susan Domchek, MD, director of the Cancer Risk Evaluation Program in the Abramson Cancer Center, is quoted in an NCI Cancer Bulletin story about the results of study of the aromatase inhibitor drug exemestane, showing that in addition to treating breast cancer, the drug also reduces the risk of invasive breast cancer among postmenopausal women at high risk of developing the disease. Though two other drugs, tamoxifen and raloxifene, are used for this purposes, neither have substantially caught on among patients, primarily because of side effect concerns. "The good news is that exemestane has a completely different toxicity profile," said Domchek, who was a site investigator on the trial. "For some women, exemestane will be viewed as a nice choice because of that difference." Read More